# Evidence Digest: Emerging Biomarkers Guiding First-Line Immunotherapy Selection
Clinical bottom line
The selection of first-line immunotherapy in oncology is increasingly guided by emerging biomarkers that may enhance patient outcomes. Biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) are being investigated for their potential to predict response to immunotherapy. While these biomarkers show promise, their clinical utility varies, and further validation is necessary to establish standardized guidelines for their use.What the evidence shows
Recent studies have identified several biomarkers that may inform the selection of immunotherapy in various cancer types:1. **PD-L1 Expression**: PD-L1 is a well-established biomarker for predicting response to PD-1 and PD-L1 inhibitors. A meta-analysis indicated that higher PD-L1 expression correlates with improved outcomes in patients receiving these therapies (PMID: 31329257). However, the threshold for PD-L1 positivity can vary across assays, leading to inconsistencies in clinical decision-making.
2. **Tumor Mutational Burden (TMB)**: TMB quantifies the number of mutations within a tumor and has been associated with response to immunotherapy. A study found that patients with high TMB had better responses to anti-PD-1 therapy compared to those with low TMB (PMID: 30876623). Nonetheless, the optimal TMB cutoff for predicting response remains debated, and standardization across testing platforms is needed.
3. **Microsatellite Instability (MSI)**: MSI is a condition of genetic hypermutability that has been linked to favorable responses to immune checkpoint inhibitors. The FDA has approved pembrolizumab for the treatment of MSI-high tumors, underscoring its clinical relevance (PMID: 29732299). However, the prevalence of MSI varies by cancer type, and its assessment may not be routinely performed in all clinical settings.
4. **Other Emerging Biomarkers**: Additional candidates such as gene expression profiles and immune-related gene signatures are under investigation. For instance, a recent study suggested that specific gene expression patterns may predict response to immunotherapy in melanoma (PMID: 33036901). These findings are preliminary and warrant further exploration.
Caveats and uncertainty
While emerging biomarkers hold promise, several caveats must be considered:- **Variability in Testing**: The methodologies for assessing biomarkers like PD-L1 and TMB can differ significantly between laboratories, leading to variability in results and interpretations.
- **Limited Generalizability**: Many studies evaluating these biomarkers are conducted in specific populations or cancer types, which may limit the applicability of findings to broader patient cohorts.
- **Dynamic Nature of Tumors**: Tumor biology can change over time, and a biomarker that predicts response at one point may not be reliable at another. This dynamic nature complicates the use of static biomarkers for treatment decisions.
- **Need for Validation**: Many emerging biomarkers require further validation in larger, diverse cohorts to confirm their predictive value and establish clinical guidelines.